Journal Article

Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock

Jean-Louis Vincent, Qinghua Sun and Marc-Jacques Dubois

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 34, issue 8, pages 1084-1093
Published in print April 2002 | ISSN: 1058-4838
Published online April 2002 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/339549
Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Sepsis remains one of the leading causes of mortality in critically ill patients. Increased insight into the complexities of this disease process has resulted in the targeting of various aspects of the inflammatory response as offering potential therapeutic benefits. There have been encouraging results in the past few years. Some of the tested agents have been shown to improve mortality rates in large randomized controlled trials involving patients with severe sepsis. In this article, we discuss the positive and negative results of trials in this field; some of the possible reasons for the negative results are examined, and directions for the future are suggested.

Journal Article.  8504 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.